[go: up one dir, main page]

ATE265460T1 - Verfahren zur herstellung von 5-lipooxygenase inhibitoren - Google Patents

Verfahren zur herstellung von 5-lipooxygenase inhibitoren

Info

Publication number
ATE265460T1
ATE265460T1 AT99309046T AT99309046T ATE265460T1 AT E265460 T1 ATE265460 T1 AT E265460T1 AT 99309046 T AT99309046 T AT 99309046T AT 99309046 T AT99309046 T AT 99309046T AT E265460 T1 ATE265460 T1 AT E265460T1
Authority
AT
Austria
Prior art keywords
producing
lipooxygenase inhibitors
lipooxygenase
inhibitors
Prior art date
Application number
AT99309046T
Other languages
English (en)
Inventor
Charles Kwok-Fung Chiu
Douglas John Meldrum Allen
Ravi Mysore Shanker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE265460T1 publication Critical patent/ATE265460T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
AT99309046T 1998-12-22 1999-11-12 Verfahren zur herstellung von 5-lipooxygenase inhibitoren ATE265460T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11322198P 1998-12-22 1998-12-22

Publications (1)

Publication Number Publication Date
ATE265460T1 true ATE265460T1 (de) 2004-05-15

Family

ID=22348241

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99309046T ATE265460T1 (de) 1998-12-22 1999-11-12 Verfahren zur herstellung von 5-lipooxygenase inhibitoren

Country Status (22)

Country Link
US (1) US6194585B1 (de)
EP (1) EP1029865B1 (de)
JP (2) JP3468729B2 (de)
KR (1) KR100362789B1 (de)
CN (1) CN1258675A (de)
AR (1) AR019497A3 (de)
AT (1) ATE265460T1 (de)
AU (1) AU6539199A (de)
BR (1) BR9905918A (de)
CA (1) CA2289422A1 (de)
CZ (1) CZ453699A3 (de)
DE (1) DE69916778D1 (de)
HU (1) HUP9904282A3 (de)
ID (1) ID24014A (de)
IL (1) IL132897A0 (de)
IN (1) IN187165B (de)
PL (1) PL337397A1 (de)
RU (1) RU2181722C2 (de)
TR (1) TR199903204A2 (de)
TW (1) TW455586B (de)
YU (1) YU59399A (de)
ZA (1) ZA997113B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4569187B2 (ja) * 2004-06-17 2010-10-27 宇部興産株式会社 4−シアノテトラヒドロピランの製法
US7674811B2 (en) 2006-03-14 2010-03-09 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
JP4469924B2 (ja) * 2006-11-27 2010-06-02 ファイザー・プロダクツ・インク ピラゾール類似体
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2021133689A2 (en) * 2019-12-23 2021-07-01 Sri International Lipoxygenase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462830B1 (de) * 1990-06-21 1995-10-18 Zeneca Limited Zyklische Ether-Derivate
IE913866A1 (en) * 1990-11-28 1992-06-03 Ici Plc Aryl derivatives
EP0505122A1 (de) * 1991-03-21 1992-09-23 Zeneca Limited Alpha, Alpha-Dialkylbenzylderivate
EP0540165A1 (de) * 1991-10-03 1993-05-05 Zeneca Limited Alkonsäurederivate
EP0703913B1 (de) * 1993-06-14 1997-06-11 Pfizer Inc. Imidazole als lipoxygenase inhibitoren
SK281577B6 (sk) * 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze
US5883106A (en) * 1994-10-18 1999-03-16 Pfizer Inc. 5-lipoxygenase inhibitors

Also Published As

Publication number Publication date
JP2004002415A (ja) 2004-01-08
ID24014A (id) 2000-06-22
EP1029865A2 (de) 2000-08-23
CN1258675A (zh) 2000-07-05
DE69916778D1 (de) 2004-06-03
HUP9904282A3 (en) 2001-04-28
AU6539199A (en) 2000-06-29
JP3468729B2 (ja) 2003-11-17
IN187165B (de) 2002-02-23
US6194585B1 (en) 2001-02-27
YU59399A (sh) 2002-11-15
AR019497A3 (es) 2002-02-20
KR100362789B1 (ko) 2002-11-30
HU9904282D0 (en) 2000-01-28
JP2000191654A (ja) 2000-07-11
TW455586B (en) 2001-09-21
TR199903204A2 (xx) 2000-07-21
RU2181722C2 (ru) 2002-04-27
PL337397A1 (en) 2000-07-03
ZA997113B (en) 2001-05-15
CZ453699A3 (cs) 2000-07-12
BR9905918A (pt) 2000-09-26
EP1029865A3 (de) 2000-11-08
IL132897A0 (en) 2001-03-19
HUP9904282A2 (hu) 2000-12-28
MX9912076A (de) 2000-04-30
KR20000052537A (ko) 2000-08-25
EP1029865B1 (de) 2004-04-28
CA2289422A1 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
ATE386736T1 (de) Verfahren zur herstellung von benzimidazol-2-yl - chinolinonderivaten
DE69913666D1 (de) Verfahren zur herstellung von di-methyl-naphthalinen
AT7110U9 (de) Verfahren zur herstellung von amlodipinmaleat
DE69911398D1 (de) Verfahren zur herstellung von 4-aminodiphenylaminen
ATE339433T1 (de) Verbessertes verfahren zur herstellung von makroliden
ATE249417T1 (de) Verfahren zur herstellung von l- phenylephrinhydrochlorid
ATE316518T1 (de) Verfahren zur herstellung von (r)-2-alkyl-3- phenyl-1-propanolen
DE50102444D1 (de) Verfahren zur herstellung von isocyanatoorganosilanen
ATE262576T1 (de) Verfahren zur herstellung von weichmittelzusammensetzungen
DE60003264D1 (de) Verfahren zur herstellung von glycerylethern
ATE266004T1 (de) Verfahren zur herstellung von 3-amino-2-chlor-4- methylpyridin
DE50111560D1 (de) Verfahren zur herstellung von guerbetalkoholen
ATE287870T1 (de) Verfahren zur herstellung von phenethylamin- derivaten
DE59901552D1 (de) Verfahren zur herstellung von polyalkylenarylaten
DE50006772D1 (de) Verfahren zur herstellung von oxindolen
DE69910995D1 (de) Verfahren zur herstellung von fluorkohlenwasserstoffen
DE60134415D1 (de) Verfahren zur herstellung von wäscheweichmacherzusammensetzungen
DE60105991D1 (de) Verfahren zur herstellung von 6-aminocapronamid
DE50001895D1 (de) Verfahren zur herstellung von phosphonomethylglycin
EP1208106A4 (de) Verfahren zur herstellung von aminopropyl- oder aminoalkyl-unktionalisierten polyalkyl- oder aryl-siloxanen
ATE265460T1 (de) Verfahren zur herstellung von 5-lipooxygenase inhibitoren
DE69901192D1 (de) Verfahren zur herstellung von cyclopropanmethylamin
ATE233238T1 (de) Verfahren zur herstellung von 3-acyl-indolen
DE69928784D1 (de) Verfahren zur herstellung von oxazolidin-2-on-derivaten
ATE327995T1 (de) Verfahren zur herstellung von camptothectin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties